|Mr. Raul R. Rodriguez||Pres, CEO & Director||992.15k||N/A||1961|
|Ms. Dolly A. Vance||Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec.||736.51k||N/A||1965|
|Dr. Anne-Marie S. Duliege||Exec. VP & Chief Medical Officer||678.35k||N/A||1959|
|Mr. Eldon C. Mayer III, M.B.A.||Exec. VP & Chief Commercial Officer||580.85k||N/A||1961|
|Dr. Thomas A. Raffin||Co-Founder||N/A||N/A||1947|
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company's clinical programs include fostamatinib, an oral spleen tyrosine kinase inhibitor for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and immunoglobulin a nephropathy. Rigel Pharmaceuticals, Inc. has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; BMS for the discovery, development, and commercialization of cancer immunotherapies; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to pursue research related to MDM2 inhibitors, a novel class of drug targets called ligases. The company was incorporated in 1996 and is based in South San Francisco, California.
Rigel Pharmaceuticals, Inc.’s ISS Governance QualityScore as of February 1, 2019 is 5. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 3; Compensation: 7.